bevacizumab-awwb vs LY01008

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

bevacizumab-awwb · MVASI

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT01966003 · Phase 3 · completed

This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.

Reported efficacy

Percentage of Participants With an Objective Response (Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.): Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). (met)

Result source: NCT01966003

LY01008

Marketed by Luye Pharma Group

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03533127 · Phase 3 · status unknown

This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.

Reported efficacy

Best Objective Response Rate (19 weeks from randomization): LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. (met)

Result source: NCT03533127

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbevacizumab-awwbLY01008
PFS, median6.6 vs 7.9vs Bevacizumabn 328NCT01966003—Not reported
OS, median—Not reported—Not reported
ORR39% vs 41.7%vs Bevacizumabn 328NCT01966003—Not reported
Duration of response, median5.8 vs 5.6vs Bevacizumabn 128NCT01966003—Not reported

PFS, median

bevacizumab-awwb
6.6 vs 7.9vs Bevacizumabn 328NCT01966003
LY01008
—Not reported

OS, median

bevacizumab-awwb
—Not reported
LY01008
—Not reported

ORR

bevacizumab-awwb
39% vs 41.7%vs Bevacizumabn 328NCT01966003
LY01008
—Not reported

Duration of response, median

bevacizumab-awwb
5.8 vs 5.6vs Bevacizumabn 128NCT01966003
LY01008
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

LY01008
LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated. NCT03533127 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. bevacizumab-awwb: 3 of 4 rows · LY01008: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbevacizumab-awwb
Dropout rate
82.3%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
26.2%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
alopecia 43.2%
nausea 25.3%
anaemia 20.1%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bevacizumab-awwb

ORR 39% (n=328) vs 41.7% (n=314) Bevacizumab
responder rate · % of participants
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 5.8 vs 5.6 Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS 6.6 vs 7.9 Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs NA Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bevacizumab-awwb's landscape · LY01008's landscape